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Distinct Tumorigenic Potential of abl
and raf in B Cell Neoplasia: abl
Activates the IL-6 Signaling Pathway
David M. Hilbert,* Thi-Sau Migone,† loci (reviewed by Potter and Wiener, 1992), while retrovi-
rally induced tumors avoid the need for spontaneousManfred Kopf,‡ Warren J. Leonard,†
translocations by expressing myc directly from the viraland Stuart Rudikoff*
genome (Troppmair et al., 1989; Largaespada et al.,*Laboratory of Genetics
1992). A second common feature is the tumor inductionNational Cancer Institute
pattern in two parental strains, BALB/c and DBA/2,National Institutes of Health
which are considered prototypical for susceptibility andBethesda, Maryland 20892
resistance, respectively (Potter, 1984; Silva et al., 1991).†Laboratory of Molecular Immunology
While this observation suggests the involvement of com-National Heart, Lung, and Blood Institute
mon genetic elements, experiments demonstrating thatNational Institutes of Health
F1 animals are susceptible to viral induction (Wiener etBethesda, Maryland 20892
al., 1995), but resistant to inflammatory agents (Potter‡Basel Institute for Immunobiology
et al., 1994b), indicate that unique loci may also contrib-CH-4005 Basel
ute to neoplastic development. To date, no specificSwitzerland
genes have been associated with any induction mecha-
nism and in the most well-studied of these systems
(pristane), a minimum of three loci have been implicatedSummary
(Mock et al., 1993; Potter et al., 1994b).
Given the difficulty of using standard genetic ap-The development of murine plasma cell tumors in-
proaches to study plasma cell tumor development, weduced by raf/myc containing retroviruses is facilitated
have attempted to define epigenetic factors that influ-by T cells and completely dependent on IL-6. To deter-
ence tumorigenesis in the context of a susceptible ge-mine whether kinases with differing specificities re-
netic background. Phenotypic differences associatedflect alternative biochemical pathways in B cell tumori-
with varying epigenetic elements are thus likely to pro-genesis, we have employed an abl/myc containing
vide insights into specific biochemical pathways ef-retrovirus to assess neoplastic development. In con-
fecting neoplastic progression. In this regard, we havetrast with raf/myc, abl/myc disease is T cell and IL-6
previously demonstrated that both T cells (Hilbert etindependent. An examination of the IL-6 signal trans-
al., 1995a) and interleukin-6 (IL-6) (Hilbert et al., 1995b)duction pathway reveals that this pathway, as defined
appear to play significant roles in raf/myc tumor induc-by activation of Stat3, is inducible by IL-6 in raf/myc
tion. In the absence of T cells (nude mice), this combina-tumors but constitutively activated in abl/myc tumors.
tion of oncogenes generates primarily B cell lympho-
These findings provide a mechanism for the derivation
mas, whereas T cell–reconstituted animals develop
of cytokine-independent plasma cell tumors and sug-
plasma cell tumors; thus, while T cells are not necessary
gest that both IL-6-dependent and independent tu-
for transformation, they are important for progressionmors may arise in vivo depending on the particular
(Hilbert et al., 1995a). IL-6 is not only an in vitro growth
mutational events incurred during tumorigenesis.
factor for primary isolates of pristane-induced plasma
cell tumors (Degrassi et al., 1993) and some established
cell lines (Nordan and Potter, 1986; Van Snick et al.,
Introduction 1987; Vink et al., 1990; Degrassi et al., 1993), but also
has recently been demonstrated to be essential for in
Plasma cell tumors can be induced in susceptible mice vivo development of raf/myc tumors, based on the ob-
following intraperitoneal introduction of plastics (Merwin servation that IL-6 knockout mice are resistant to B cell
and Algire, 1959), mineral oils (Potter and Boyce, 1962), neoplasia (Hilbert et al., 1995b). T cells and IL-6 also
silicone polymers (Potter et al., 1994a), or alkanes such appear to be involved in the similar human disease,
as pristane (2,6,10,14 tetramethylpentadecane) (Ander- multiple myeloma. Circulating abnormal B cells have
son and Potter, 1969; Potter and Wax, 1983). Each of been described in a number of myeloma patients (Jen-
these inducing agents initiates a localized inflammatory sen et al., 1991, 1992, 1993) and, in some cases, these
response that leads to the formation of chronic granulo- cells have been found to be clonally related to the re-
matous tissue in which plasma cell tumors ultimately sulting malignant plasma cells (Kubagawa et al., 1979;
develop. Phenotypically indistinguishable tumors can Bast et al., 1982; King and Nelson, 1989; Van Riet et al.,
also be induced by oncogene containing retroviruses 1989; Cassel et al., 1990; Osterborg et al., 1991; Billa-
such as J3V1 (which expresses raf and myc) (Troppmair deau et al., 1992, 1993), consistent with the possibility
et al., 1989; Kurie et al., 1990; Hilbert et al., 1993) and that normal T cells may be driving “transformed” B cells
ABL–MYC (which expresses abl and myc) (Largaespada to terminal differentiation. As in the murine system, IL-6
et al.,1992). At least twofeatures are knownto be shared has been suggested to be the primary growth factor
among these various induction protocols. First, all tu- involved in this human malignancy, as many lines de-
mors are characterized by high levelconstitutive expres- rived from myeloma patients proliferate in response to
sion of the myc oncogene. Tumors induced by inflamma- this cytokine (Kawano et al., 1988; Bergui et al., 1989;
tory agents deregulate myc by translocation of an Shimizu et al., 1989; Klein et al., 1989; Hitzler et al., 1991;
Zhang et al., 1994). Moreover, in recent in vivo studies,endogenous c-myc gene into one of the immunoglobulin
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Table 1. Comparison of Cell Surface Phenotype and Hematopoietic Lineage Association of raf/myc- and abl/myc-Induced Tumors
Arising in BALB/c and DBA/2 Mice
Mouse strain abl/myc-induced tumors raf/myc-induced tumors
B lineage
Plasma cell Plasma cell B lymphoma Myeloid
BALB/c
DBA/2 None None None
All mice received 0.5 ml pristane intraperitoneally 2 days prior to intraperitoneal injection of 1.25 3 105 ffu of the indicated virus. Analyses
were performed on tumor cells recovered from ascites of tumor-bearing mice.
transient tumor inhibition was observed following treat- based on immunoglobulin secretion (data not shown)
and invariable expression of the mature B lineagement with anti-IL-6 (Klein et al., 1991) or anti-IL-6R (Su-
zuki et al., 1992). Thus, further delineation of the roles marker ThB, and the lack of expression of earlier stage
markers CD45R(B220) (Table 1) and major histocompati-of T cells and IL-6 in murine plasma cell disease may
provide important corollaries to human myeloma. bility complex (MHC) class II (data not shown). This same
phenotype is characteristic of plasma cell tumors in-In the current report, we have investigated whether
the roles of T cells and IL-6 are restricted to raf/myc- duced by raf/myc, but, in contrast, the raf/myc combina-
tion also produces significant numbers of myeloid tu-mediated disease or whether other induction protocols
may differentially affect associated biochemical path- mors that are primarily mature macrophages expressing
high levels of CD11b (Mac-1) and, in approximately halfways. Accordingly, we have assessed the tumorigenic
potential of raf/myc and abl/myc expressing retrovi- of the cases, coexpressing MHC class II determinants
(Table 1). B cell lymphomas, which are readily distin-ruses that encode distinct kinase specificities, with v-raf
encoding a serine–threonine kinase (Moelling et al., guished from plasma cell tumors by lack of ThB and
high expression of both CD45R(B220) and MHC class1984; Troppmair et al., 1989) and v-abl encoding a tyro-
sine kinase (Largaespada et al., 1992). Thus, any differ- II determinants, are rarely seen, although this is the
predominant tumor phenotype in the absence of T cellsences related to tumor development or phenotype are
likely attributable to the kinase specificities of raf and (see below). DBA/2 mice are resistant to B lineage tumor
development with either virus, although myeloid tumorsabl. It was of particular interest to determine whether
the recently described ability of T cells to dictate raf/ are also observed with raf/myc. Thus, in vivo trans-
forming activity of abl/myc is restricted to the B lineage,myc tumor phenotype (Hilbert et al., 1995a), and the
absolute dependency of these tumors on IL-6 (Hilbert whereas raf/myc also transforms myeloid cells.
et al., 1995b) would be manifested in abl/myc disease.
Our results indicate that abl/myc plasma cell tumor de-
velopment, unlike that of raf/myc, is both T cell and IL-6 Host-Derived Components Influencing
abl/myc and raf/myc Tumorigenesisindependent. Although v-abl and v-raf induce virtually
identical plasma cell diseases, abl circumvents the re- Recent studies using raf/myc induction protocols have
demonstrated that T cells serve to facilitate the differen-quirement for IL-6 by constitutive activation of the en-
dogenous signal transduction pathway. These findings tiation of B cell lymphomas into mature antibody-secre-
ting plasmacytomas (Hilbert et al., 1995a). Thus, it wasmay have important implications for the progression of
cytokine-independent plasma cell tumors and for the of interest to determine whether the effect of T cells was
restricted to this particular induction system or was adevelopment of treatment regimens in human myeloma.
more generalized phenomenon. To investigate this pos-
sibility, we have compared the phenotypes of B lineageResults
tumors arising in pristane-treated T cell–deficient nude
mice receiving either raf/myc or abl/myc virus (Table 2).Phenotypes of abl/myc- and
raf/myc-Induced Tumors In contrast with the predominant plasma cell tumors
induced in normalBALB/c mice, themajority of B lineagePhenotypes were determined for abl/myc tumors in-
duced in BALB/c mice and compared with those pre- tumors arising in raf/myc-treated BALB/c.nu/nu mice
were CD45R(B220)1 B cell lymphomas with plasma cellviously reported for raf/myc induction (Hilbert et al.,
1995a, 1995b). All abl/myc tumors were plasmacytomas tumors found at a significantly lower incidence. CD11b1
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Table 2. Comparison of Incidence, Latency, and Phenotype of raf/myc- and abl/myc-Induced Tumors in Normal and Nude Mice
Number of tumors displaying indicated phenotyped
Number of Virus Tumor Tumor Plasma B cell T cell
Genotype mice treatmenta incidenceb latencyc cell tumor lymphoma lymphoma Myeloid
BALB/c 30 raf/myc 80 (24/30) 78 6 5 17 0 0 7
BALB/c. nu/nue 70 raf/myc 85 (60/70) 64 6 8 8 16 0 36
DBA/2 20 raf/myc 65 (13/20) NDf 0 0 0 13
BALB/c 15 abl/myc 80 (12/15) 40 6 3 10 0 1 1
BALB/c. nu/nu 10 abl/myc 80 (8/10) 39 6 2 8 0 0 0
DBA/2 10 abl/myc 0 (0/10) — 0 0 0 0
a Mice received 0.5 ml of pristane intraperitoneally 2–3 days prior to injection (intraperitoneally) of 12,500 focus forming units of the indicated
virus.
b Percent tumor-bearing mice (number of mice with tumor/total number of mice).
c Number of days between virus injection and appearance of tumor 6 SEM.
d Cell surface phenotypes were determined by flow cytometric and immunohistologic analyses as described in Experimental Procedures.
e Data for raf/myc induction are taken from Hilbert et al. (1995a).
f Not determined.
myeloid tumors developed at a frequency similar to that ment, four tumors from 1/1 mice were transplanted
into 2/2 recipients. Of the four, three grew in transplant,seen in normal mice. In contrast, abl/myc treatment
yielded exclusively ThB1 plasma cell tumors, indicating indicating that abl/myc obviates the IL-6 requirement
manifested in raf-mediated tumorigenesis in both 1/1that abl/myc disease progresses via a T cell–indepen-
dent pathway. and 2/2 mice.
The induction of plasma cell tumors by raf/myc has
also been found to be IL-6 dependent in vivo, as IL-6 Activation of the IL-6 Signal
Transduction Pathwayknockout mice are completely resistant to development
of this disease (Hilbert et al., 1995b). To determine The ability of abl/myc retrovirus to induce IL-6-indepen-
dent plasma cell tumors is, in some ways, analogous towhether the IL-6 requirement also extends to other on-
cogenic combinations such as abl/myc, induction ex- the development of IL-2-independent growth of T cells
following HTLV-I transformation (Maeda et al., 1987).periments were performed in IL-6 knockout mice. As
seen in Table 3, plasma cell tumors were observed at IL-2 growth independence has subsequently been cor-
related with constitutive activation of Janus kinasesan incidence of 50% in 2/2 animals, in contrast with
the complete absence of such tumors with raf/myc. The (JAKs) and signal transducers and activators of tran-
scription (STATs) induced by IL-2 (Migone et al., 1995).latency of tumors was significantly longer in these ani-
mals and induction in both genotypes (1/1 and 2/2) This result raises the possibility that IL-6 independence
among abl/myc tumors may reflect the ability of ablwas pristane dependent, as only one tumor was found
in mice not receiving pristane. To test whether tumors to constitutively activate the IL-6 signal transduction
pathway. Conversely, the IL-6-dependent developmentarising in normal animals were also IL-6 independent,
even though they arose in an IL-6-containing environ- of raf/myc tumors may indicate an inability of raf to
Table 3. Comparison of Incidence, Latency, and Phenotype of raf/myc- and abl/myc-Induced Tumors in Normal and IL-6-Deficient
Mice
Number of tumors displaying indicated phenotyped
Number of Virus Tumor Tumor Plasma B cell T cell
Genotype Pristane mice treatmenta incidenceb latencyc cell tumor lymphoma lymphoma Myeloid
BALB/c 1 30 raf/myc 80 (24/30) 78 6 5 17 0 0 7
1/1e 1 47 raf/myc 47 (22/47) 88 6 5 16 1 0 15
2/2 1 35 raf/myc 48 (16/35) 98 6 7 0 1 2 13
DBA/2 1 20 raf/myc 65 (13/20) NDf 0 0 0 13
BALB/c 1 15 abl/myc 80 (12/15) 40 6 3 10 0 1 1
1/1 1 27 abl/myc 74 (20/27) 43 6 2 20 0 0 0
2/2 1 30 abl/myc 50 (15/30) 54 6 3 15 0 0 0
1/1 2 5 abl/myc 0 (0/5) 0 0 0 0
2/2 2 19 abl/myc 5 (1/19) 100 1 0 0 0
DBA/2 1 10 abl/myc 0 (0/10) — 0 0 0 0
a Mice received 0.5 ml of pristane intraperitoneally 2–3 days prior to injection (intraperitoneally) of 12,500 focus forming units of the indicated
virus.
b Percent tumor-bearing mice (number of mice with tumor/total number of mice).
c Number of days between virus injection and appearance of tumor 6 SEM.
d Cell surface phenotypes were determined by flow cytometric and immunohistologic analyses as described in Experimental Procedures.
e Data for raf/myc induction in 1/1 and 2/2 mice taken from Hilbert et al. (1995b).
f Not determined.
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Figure 1. EMSA Assay for STAT Proteins
Extracts were prepared from cell lines derived from tumors induced by raf/myc (7.2 and 16.1), abl/myc (121.1 and 128.3), and pristane (T1165)
grown under the following conditions: plus, continual presence of IL-6; minus, IL-6 removed for 12–18 hr; and 20 min, IL-6 removed for 12–18
hr followed by a 20 min pulse with IL-6. Extracts were incubated with the FcgRI probe prior to electrophoresis.
subvert the normalcontrol of IL-6-mediated signal trans- labeled probe in either the absence (minus) or presence
(plus) of a Stat3-specific antisera capable of inhibitingduction. Therefore, we generated cell lines from raf/
myc- and abl/myc-induced tumors and determined the the formationof protein–DNA complexes (Figure 2). Anti-
bodies to Stat3 inhibited the majority of complex forma-activation state of STAT proteins previously shown to
mediate cytokine signal transduction. For these experi- tion in all lines, irrespective of inducing agent. Thus,
Stat3 appears to be the principal species inducible inments, we first assessed the ability of nuclear extracts
from the various cell lines to alter the mobility of a 32P- raf/myc and constitutively expressed in abl/myc tumors.
Immunoprecipitations using antibodies to Stat3 fol-labeled DNA probe encoding an interferon-g-activating
sequence (GAS) motif from the FcgRI gene (Migone et lowed by blotting with antibodies to either phosphotyro-
sine or Stat3 (Figure 3) demonstrated that Stat3 protein,al., 1995). Extracts were prepared from each cell line
grown in the presence of IL-6, in the absence of IL-6, while present in all lines, was phosphorylated in raf/myc
tumors only after exposure to IL-6 but was constitutivelyand from cells deprived of cytokine for 12–18 hr and
subsequently pulsed with 1.3 nM rIL-6 for 20 min. As phosphorylated in the abl/myc tumors as suggested
from mobility shift assays. Similar experiments with anti-shown in Figure 1, extracts from raf/myc lines grown
either in the presence of, or stimulated for 20 min with bodies to Stat5 (Figure 3) again indicated universal pres-
ence, but phosphorylation, which was constitutive andIL-6 contained significant DNA binding activity. How-
ever, extracts from the same lines grown in the absence not related to IL-6 treatment, was seen only in the abl/
myc lines. Immunoprecipitation with antibodies to Stat1of IL-6 did not alter probe mobility. An identical mobility
shift pattern was seen in the IL-6-dependent pristane- and Stat6 (data not shown) also revealed the presence
of these proteins in all lines, but they were only detectedinduced T1165 cell line. In contrast, all extracts from
abl/myc lines contained DNA binding activity with no in unactivated nonphosphorylated forms, even in the
presence of IL-6.significant difference seen between cells grown in the
presence or absence of IL-6.
Since Stat3 is the predominant STAT activated follow-
ing IL-6–IL-6R interaction (Zhong et al., 1994; Akira et Discussion
al., 1994; Stahl et al., 1994; Henttinen et al., 1995; Wang
et al., 1995), it was of interest to determine the extent of The present studies compare the tumorigenic potential
of raf/myc and abl/myc containing retroviruses in nor-binding activity detected in the various lines associated
with activation of this particular STAT. Accordingly, ex- mal, T cell–deficient, and IL-6-deficient mice. Pheno-
typic differences associated with the two retroviraltracts from IL-6-stimulated cells were incubated with
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Figure 2. Inhibition of EMSA by Antibodies to
Stat3
Extracts from cell lines (see legend to Figure
1) grown in IL-6 were incubated with the
FcgRI probe in the absence (minus) or pres-
ence (plus) of antibodies to Stat3 prior to elec-
trophoresis.
constructs employed in these studies must reflect alter- for end stage malignant plasma cells. Such a multistage
role is consistent with the observed requirement for IL-6native mechanisms generated by exchange of a single
oncogene (raf versus abl). Although the pattern of tumor in the development of primary immune responses (Hil-
bert et al., 1989) and as a proliferation/differentiationoccurrence in prototypic susceptible (BALB/c) and re-
sistant (DBA/2) mouse strains is identical with the two signal (Takatsuki et al., 1988; Okano et al., 1989; Beagley
et al., 1989). Nevertheless, the role of IL-6 in neoplasticviruses, each displays distinct requirements for T cells
and IL-6. Induction of plasma cell tumors by raf/myc is development must clearly be unique, since normal B
lineage development can occur in the absence of thisfacilitated by T cells in that nude mice develop primarily
B cell lymphomas, whereas reconstitution with T cells cytokine as demonstrated by the presence of both B
and plasma cells in IL-6 null animals (Ramsay et al.,leads toa reversion to the plasma cell phenotype (Hilbert
et al., 1995a). In contrast, abl/myc induces exclusively 1994; Kopf et al., 1994).
In contrast with the absolute requirement of raf/mycplasma cell tumors in nude mice, bypassing the role of
T cells. This observation suggests that abl activates for IL-6, abl/myc induces plasma cell tumors in 2/2
animals at a frequency (50%) only slightly lower thangenes that would normally be induced by T cells (or
their products). One obvious candidate for such a role controls (74%, Table 3). The abl/myc combination, thus,
obviates the role of both T cells and IL-6. Tumors arisingis IL-6, which has beensuggested to be the major growth
factor for both murine and human plasma cell neopla- in 1/1 animals arealso IL-6 independent,as the majority
can be transplanted in 2/2 animals. While the abl/mycsias. However, it should be noted that IL-6 is produced
by a variety of cell types and thus the absence of T cells tumors induced in the present studies appear to be
almost exclusively IL-6 independent, it is likely that theyas a source might not critically alter the availability of
this cytokine. It is, however, interesting that T cells from have other growth requirements related topristane prim-
ing, as only a single tumor was obtained in 2/2 micemyeloma patients have been shown to produce elevated
levels of IL-6 (Lapena et al., 1996) in addition to stromal not receiving pristane and none were obtained in 1/1
animals under the same conditions. This result is inelements inboth mice (Degrassi et al., 1993) and humans
(Uchiyama et al., 1993; Lokhorst et al., 1994). contrast with a suggested priming independence pre-
viously reported (Largaespada et al., 1992), but is inThe critical role of IL-6 in raf/myc induction of plasma
cell tumors is evidenced by the fact that IL-6 knockout agreement with the apparent dependence of some abl-
derived plasma cell tumor lines on feeder cells, IL-6, ormice are completely resistant to development of these
tumors (Hilbert et al., 1995b). Surprisingly, however, both (Sugiyama et al., 1991). The current studies do not
rule out the possibility that a subset of abl/myc tumors,these mice do not develop B cell neoplasias, even
though B cell lymphomas occur at high incidence in possibly represented by the 24% difference in incidence
between 1/1 and 2/2 animals are, in fact, IL-6 de-nude mice. This result indicates that IL-6 might be re-
quired at multiple steps in the progression of B cell pendent.
To examine mechanisms by which abl/myc tumorsneoplasia and not just as a survival/proliferation signal
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pathway correlates with the ability of abl/myc tumors
to achieve cytokine independence. Interestingly, consti-
tutive activation of Stat5 was also observed, but some
degree of specificity is apparent in that Stat1 and Stat6,
while present, are not phosphorylated. The activation
of Stat5 may indicate a role of other pathways in the
development of abl/myc tumors, which is consistent
with the requirement for pristane treatment noted above.
Stat5 has been associated with IL-2 and IL-7 signal
transduction, although neither of these has been impli-
cated in the development of plasma cell tumors. The
ability of viral proteins to circumvent normal cytokine
signaling may be a more general mechanism by which
such agents induce cellular changes. A similar role for
v-abl in the development of pre-B cell tumors has re-
cently been indicated by Danial et al. (1995) with the
demonstration of constitutive activation of the IL-4 and
IL-7 pathways in v-abl-transformed pre-B cell lines.
HTLV-I has also been shown to activate comparably
the IL-2 pathway in peripheral T cells leading to IL-2
independence (Migone et al., 1995). However, the pres-
ent comparison between IL-6-dependent (raf/myc) and
IL-6-independent (abl/myc) tumors in which cytokine
independence appears associated with constitutive ac-
tivation of the corresponding signal transduction path-
way suggests that constitutive activation leading to IL-6
independence may represent an obligatory event in this
neoplastic progression. The relevance of the present
studies in neoplasia is suggested by several observa-
tions. First, expression of Bcr–Abl as a fusion protein
resulting from a tumor-specific t(9,22) translocation is
characteristic of chronic myelogenous leukemia (Saw-
yers, 1992). Second, interaction of abl with Ras appearsFigure 3. Immunoprecipitation Analysis of Stat3 and Stat5
critical in the development of certain other leukemias
Extracts from cell lines (see legend to Figure 1) grown in the absence
(Sawyers et al., 1995). And, third, a variety of mutations(minus) or presence (plus) of IL-6 were incubated with antibodies
in c-abl can result in transformation (Franz et al., 1989;to Stat3 or Stat5. Precipitates were electrophoresed, transferred to
nitrocellulose, and developed with antibodies to phosphotyrosine Jackson and Baltimore, 1989; Goga et al., 1993). Thus,
or the precipitating antibody. in many cell types, alterations in normal abl expression
may lead to transformation through activation of signal
transduction pathways necessary for cell growth.
may become IL-6 independent, we have assessed the The experiments described here define both IL-6-de-
status of the IL-6 signal transduction pathway. Binding pendent and IL-6-independent forms of plasma cell tu-
of IL-6 to its receptor, composed of an 80 kDa cytokine- mors. The existence of these differing phenotypes is of
specific polypeptide (Yamasaki et al., 1988) associated extreme importance in considering therapeutic ap-
with gp 130 (Taga et al., 1989; Hibi et al., 1990), a signal- proaches to this disease in either animal models or
transducing element common to a number of cytokine humans. The number of similarities between murine
receptors, leads to activation of JAK kinases (Narazaki plasma cell tumors and human myeloma makes it ap-
et al., 1994; Stahl et al., 1994; Matsuda et al., 1994; pear likely that comparable phenotypes will exist in both
Henttinen et al., 1995). These kinases (Jak1, Jak2, and species. Currently, the percentage of patients pre-
TYK2) subsequently phosphorylate and activate cyto- senting with IL-6-dependent versus independent dis-
plasmic transcription factors (STATs), principally Stat3 ease is not known, nor is the frequency at which IL-6-
in the IL-6 pathway (Zhong et al., 1994; Akira et al., 1994; dependent disease evolves into an independent form.
Stahl et al., 1994; Henttinen et al., 1995; Wang et al., Initial studies using antibodies to IL-6 or IL-6R (Klein et
1995), which translocate to the nucleus and modulate al., 1991; Suzuki et al., 1992) have provided an indication
expression of target genes (Nakajima et al., 1995). Analy- of transient tumor modulation, although the general ap-
sis of raf/myc tumors (Figures 2 and 3) revealed that plicability of therapeutic approaches to this class of
activation of the IL-6 signal transduction pathway is disease through modulation of IL-6, either by antibodies
completely dependent on the addition of exogenous or specific inhibitors (Savino et al., 1994; de Hon et al.,
IL-6. Cells grown in the absence of IL-6 do not demon- 1994; Hartman et al., 1995; Palumbo et al., 1995; Brosh
strate Stat3 activation, but such activation occurs rap- et al., 1995; Martin et al., 1996), remains unclear. Obvi-
idly upon addition of cytokine. In contrast, Stat3 is con- ously, if IL-6-independent myeloma, corresponding to
stitutively activated in abl/myc tumors in the absence that produced by abl/myc, occurs at a significant fre-
quency, alternate forms of therapy will be required. Ofof cytokine. Thus, constitutive activation of the IL-6
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grown in medium only or stimulated with IL-6. In brief, cells wereequal importance to the herein established generation
washed with phosphate-buffered saline and lysed in 10 mM Trisof IL-6-independent tumors is the observation that origi-
(pH 7.5) containing 2 mM EDTA, 0.15 M NaCl, 0.875% Brij 97, 0.125%nally IL-6-dependent tumors (the raf/myc tumors in the
Nonidet-P40, 0.4 mM sodium orthovanadate, 4 mM sodium flouride,
current study) can rapidly evolve into IL-6-independent 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochlorine, 2.5
forms upon gradual removal of IL-6. Thus, a similar se- mM leupeptin, and 2.5 mM aprotinin. Immunoprecipitations were
performed using antibodies specific for Stat1, Stat3, Stat6 (Santalection may likely occur in vivo. In these tumors, the IL-6
Cruz Biotechnology, Incorporated, Santa Cruz, California), and Stat5signal transduction pathway remains inducible and is
(Dr. A. Larner, Food and Drug Administration, Bethesda, Maryland).not constitutively activated as with abl/myc. Therefore,
Proteins were separated on 8% SDS–PAGE and transferred to Im-such tumors must become IL-6 independent through
mobilon Pmembranes (Millipore, Bedford, Massachusetts).Western
additional mechanisms that may not even involve JAKs blotting was performed with antibodies to phosphotyrosine (4G10,
and STATs, further indicating the need for non-IL-6- Upstate Biotechnology, Incorporated, Lake Placid, New York), anti-
Stat3, or anti-Stat5 (Transduction Laboratories, Incorporated, Lex-directed therapies. Future studies to define these
ington, Kentucky) and visualized by enhanced chemiluminescencealternate mechanisms by which IL-6 independence is
(Pierce, Rockford, Illinois).achieved are likely to provide direction to the search for
additional treatments.
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